Call for research proposals on “Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy”
TRANSCAN-3 partners have agreed to focus their second Joint Transnational Call for proposals (JTC 2022) on :
“Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy”
Survival rate for most cancers has doubled over the past 40 years, with 50% of patients surviving to 10 years or longer. However, progress has not advanced equally for all forms of cancer. According to the most authoritative cancer epidemiology registries in the Western world (e.g., the NIH Surveillance, Epidemiology, and End Results (SEER) Program, https://seer.cancer.gov or the IARC Cancer Survival in High-Income Countries (SURVMARK-2) project, https://gco.iarc.fr/survival/survmark), survival for some types of cancer is lagging behind, due to the lack of successful treatment. For some Hard-To-Treat Cancers (HTTC), the 5-year survival rate is still lower than 35% and little or no improvement has occurred in the past decades; these include tumours arising in the oesophagus, liver and annexes, pancreas, lung/pleura, and brain.
Aims of the Call
Identification/validation of novel early diagnostic approaches.
Identification/validation of novel therapeutic approaches.
Development of novel drug delivery strategies.
23 May 2022 : Publication of the call
18 July 2022 at 12:00 (CEST) : Deadline for pre-proposal submission
15 December 2022 at 12:00 (CET) : Deadline for full-proposal submission